collection
https://read.qxmd.com/read/28943066/2017-aha-acc-clinical-performance-and-quality-measures-for-adults-with-st-elevation-and-non-st-elevation-myocardial-infarction-a-report-of-the-american-college-of-cardiology-american-heart-association-task-force-on-performance-measures
#1
JOURNAL ARTICLE
Hani Jneid, Daniel Addison, Deepak L Bhatt, Gregg C Fonarow, Sana Gokak, Kathleen L Grady, Lee A Green, Paul A Heidenreich, P Michael Ho, Corrine Y Jurgens, Marjorie L King, Dharam J Kumbhani, Samir Pancholy
No abstract text is available yet for this article.
October 17, 2017: Journal of the American College of Cardiology
https://read.qxmd.com/read/28855272/pathophysiology-diagnosis-and-treatment-of-tachycardiomyopathy
#2
REVIEW
Claire A Martin, Pier D Lambiase
No abstract text is available yet for this article.
October 2017: Heart
https://read.qxmd.com/read/25720452/pathogenic-immunity-in-systemic-lupus-erythematosus-and-atherosclerosis-common-mechanisms-and-possible-targets-for-intervention
#3
REVIEW
M Wigren, J Nilsson, M J Kaplan
Systemic lupus erythematosus (SLE) is an autoimmune disorder that primarily affects young women and is characterized by inflammation in several organs including kidneys, skin, joints, blood and nervous system. Abnormal immune cellular and humoral responses play important roles in the development of the disease process. Impaired clearance of apoptotic material is a key factor contributing to the activation of self-reactive immune cells. The incidence of atherosclerotic cardiovascular disease (CVD) is increased up to 50-fold in patients with SLE compared to age- and gender-matched controls, and this can only partly be explained by traditional risk factors for CVD...
November 2015: Journal of Internal Medicine
https://read.qxmd.com/read/24633413/primary-cardiac-disease-in-systemic-lupus-erythematosus-patients-protective-and-risk-factors-data-from-a-multi-ethnic-latin-american-cohort
#4
JOURNAL ARTICLE
Mercedes A García, Graciela S Alarcón, Gabriela Boggio, Leticia Hachuel, Ana Inés Marcos, Juan Carlos Marcos, Silvana Gentiletti, Francisco Caeiro, Emilia I Sato, Eduardo F Borba, João C Tavares Brenol, Loreto Massardo, José Fernando Molina-Restrepo, Gloria Vásquez, Marlene Guibert-Toledano, Leonor Barile-Fabris, Mary-Carmen Amigo, Guillermo F Huerta-Yáñez, Jorge M Cucho-Venegas, Rosa Chacón-Diaz, Bernardo A Pons-Estel
OBJECTIVES: The aim of this study was to assess the cumulative incidence, risk and protective factors and impact on mortality of primary cardiac disease in SLE patients (disease duration ≤2 years) from a multi-ethnic, international, longitudinal inception cohort (34 centres, 9 Latin American countries). METHODS: Risk and protective factors of primary cardiac disease (pericarditis, myocarditis, endocarditis, arrhythmias and/or valvular abnormalities) were evaluated...
August 2014: Rheumatology
https://read.qxmd.com/read/28571635/%C3%AE-blockers-and-mortality-after-acute-myocardial-infarction-in-patients-without-heart-failure-or-ventricular-dysfunction
#5
MULTICENTER STUDY
Tatendashe B Dondo, Marlous Hall, Robert M West, Tomas Jernberg, Bertil Lindahl, Hector Bueno, Nicolas Danchin, John E Deanfield, Harry Hemingway, Keith A A Fox, Adam D Timmis, Chris P Gale
BACKGROUND: For acute myocardial infarction (AMI) without heart failure (HF), it is unclear if β-blockers are associated with reduced mortality. OBJECTIVES: The goal of this study was to determine the association between β-blocker use and mortality in patients with AMI without HF or left ventricular systolic dysfunction (LVSD). METHODS: This cohort study used national English and Welsh registry data from the Myocardial Ischaemia National Audit Project...
June 6, 2017: Journal of the American College of Cardiology
https://read.qxmd.com/read/28455343/2017-acc-aha-hfsa-focused-update-of-the-2013-accf-aha-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of-cardiology-american-heart-association-task-force-on-clinical-practice-guidelines-and-the-heart-failure-society-of-america
#6
REVIEW
Clyde W Yancy, Mariell Jessup, Biykem Bozkurt, Javed Butler, Donald E Casey, Monica M Colvin, Mark H Drazner, Gerasimos S Filippatos, Gregg C Fonarow, Michael M Givertz, Steven M Hollenberg, JoAnn Lindenfeld, Frederick A Masoudi, Patrick E McBride, Pamela N Peterson, Lynne Warner Stevenson, Cheryl Westlake
No abstract text is available yet for this article.
August 8, 2017: Circulation
https://read.qxmd.com/read/28286221/2017-acc-aha-hrs-guideline-for-the-evaluation-and-management-of-patients-with-syncope-a-report-of-the-american-college-of-cardiology-american-heart-association-task-force-on-clinical-practice-guidelines-and-the-heart-rhythm-society
#7
JOURNAL ARTICLE
Win-Kuang Shen, Robert S Sheldon, David G Benditt, Mitchell I Cohen, Daniel E Forman, Zachary D Goldberger, Blair P Grubb, Mohamed H Hamdan, Andrew D Krahn, Mark S Link, Brian Olshansky, Satish R Raj, Roopinder Kaur Sandhu, Dan Sorajja, Benjamin C Sun, Clyde W Yancy
No abstract text is available yet for this article.
August 1, 2017: Journal of the American College of Cardiology
https://read.qxmd.com/read/28249994/duration-of-dual-antiplatelet-therapy-in-acute-coronary-syndrome
#8
REVIEW
Simon John Wilson, David E Newby, Dana Dawson, John Irving, Colin Berry
Despite a large volume of evidence supporting the use of dual antiplatelet therapy in patients with acute coronary syndrome, there remains major uncertainty regarding the optimal duration of therapy. Clinical trials have varied markedly in the duration of therapy, both across and within trials. Recent systematic reviews and meta-analyses suggest that shorter durations of dual antiplatelet therapy are superior because the avoidance of atherothrombotic events is counterbalanced by the greater risks of excess major bleeding with apparent increases in all-cause mortality with longer durations...
April 2017: Heart
https://read.qxmd.com/read/28190140/complete-repair-of-tetralogy-of-fallot-in-the-neonatal-versus-non-neonatal-period-a-meta-analysis
#9
REVIEW
Rohit S Loomba, Matthew W Buelow, Ronald K Woods
It is unclear if neonatal tetralogy of Fallot repair offers better outcomes compared to repair later in infancy. We therefore conducted a meta-analysis comparing outcomes of neonatal and non-neonatal repair. Manuscripts were identified and reviewed for quality and bias with favorably scored manuscripts being included in the final meta-analysis. Several perioperative and postoperative variables were compared. A total of 8 studies with 3858 patients were included in the analysis. Of these patients, 19% underwent neonatal repair...
June 2017: Pediatric Cardiology
https://read.qxmd.com/read/28104075/challenges-in-infective-endocarditis
#10
REVIEW
Thomas J Cahill, Larry M Baddour, Gilbert Habib, Bruno Hoen, Erwan Salaun, Gosta B Pettersson, Hans Joachim Schäfers, Bernard D Prendergast
Infective endocarditis is defined by a focus of infection within the heart and is a feared disease across the field of cardiology. It is frequently acquired in the health care setting, and more than one-half of cases now occur in patients without known heart disease. Despite optimal care, mortality approaches 30% at 1 year. The challenges posed by infective endocarditis are significant. It is heterogeneous in etiology, clinical manifestations, and course. Staphylococcus aureus, which has become the predominant causative organism in the developed world, leads to an aggressive form of the disease, often in vulnerable or elderly patient populations...
January 24, 2017: Journal of the American College of Cardiology
https://read.qxmd.com/read/27659469/contrast-induced-acute-kidney-injury
#11
REVIEW
Peter A McCullough, James P Choi, Georges A Feghali, Jeffrey M Schussler, Robert M Stoler, Ravi C Vallabahn, Ankit Mehta
Coronary angiography and percutaneous intervention rely on the use of iodinated intravascular contrast for vessel and chamber imaging. Despite advancements in imaging and interventional techniques, iodinated contrast continues to pose a risk of contrast-induced acute kidney injury (CI-AKI) for a subgroup of patients at risk for this complication. There has been a consistent and graded signal of risk for associated outcomes including need for renal replacement therapy, rehospitalization, and death, according to the incidence and severity of CI-AKI...
September 27, 2016: Journal of the American College of Cardiology
https://read.qxmd.com/read/20579534/bicuspid-aortic-valve-disease
#12
REVIEW
Samuel C Siu, Candice K Silversides
Bicuspid aortic valve (BAV) disease is the most common congenital cardiac defect. While the BAV can be found in isolation, it is often associated with other congenital cardiac lesions. The most frequent associated finding is dilation of the proximal ascending aorta secondary to abnormalities of the aortic media. Changes in the aortic media are present independent of whether the valve is functionally normal, stenotic, or incompetent. Although symptoms often manifest in adulthood, there is a wide spectrum of presentations ranging from severe disease detected in utero to asymptomatic disease in old age...
June 22, 2010: Journal of the American College of Cardiology
https://read.qxmd.com/read/27742798/understanding-sudden-death-risk-in-tetralogy-of-fallot-from-bedside-to-bench
#13
EDITORIAL
Stephen Seslar, Melissa Robinson
No abstract text is available yet for this article.
March 2017: Heart
https://read.qxmd.com/read/27681577/update-on-hypertrophic-cardiomyopathy-and-a-guide-to-the-guidelines
#14
REVIEW
Srijita Sen-Chowdhry, Daniel Jacoby, James C Moon, William J McKenna
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disorder, affecting 1 in 500 individuals worldwide. Existing epidemiological studies might have underestimated the prevalence of HCM, however, owing to limited inclusion of individuals with early, incomplete phenotypic expression. Clinical manifestations of HCM include diastolic dysfunction, left ventricular outflow tract obstruction, ischaemia, atrial fibrillation, abnormal vascular responses and, in 5% of patients, progression to a 'burnt-out' phase characterized by systolic impairment...
November 2016: Nature Reviews. Cardiology
https://read.qxmd.com/read/27043774/aliskiren-enalapril-or-aliskiren-and-enalapril-in-heart-failure
#15
RANDOMIZED CONTROLLED TRIAL
John J V McMurray, Henry Krum, William T Abraham, Kenneth Dickstein, Lars V Køber, Akshay S Desai, Scott D Solomon, Nicola Greenlaw, M Atif Ali, Yanntong Chiang, Qing Shao, Georgia Tarnesby, Barry M Massie
BACKGROUND: Among patients with chronic heart failure, angiotensin-converting-enzyme (ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such patients is unknown. We compared the ACE inhibitor enalapril with the renin inhibitor aliskiren (to test superiority or at least noninferiority) and with the combination of the two treatments (to test superiority) in patients with heart failure and a reduced ejection fraction. METHODS: After a single-blind run-in period, we assigned patients, in a double-blind fashion, to one of three groups: 2336 patients were assigned to receive enalapril at a dose of 5 or 10 mg twice daily, 2340 to receive aliskiren at a dose of 300 mg once daily, and 2340 to receive both treatments (combination therapy)...
April 21, 2016: New England Journal of Medicine
https://read.qxmd.com/read/27567407/2016-esc-eas-guidelines-for-the-management-of-dyslipidaemias
#16
JOURNAL ARTICLE
Alberico L Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M John Chapman, Heinz Drexel, Arno W Hoes, Catriona S Jennings, Ulf Landmesser, Terje R Pedersen, Željko Reiner, Gabriele Riccardi, Marja-Riita Taskinen, Lale Tokgozoglu, W M Monique Verschuren, Charalambos Vlachopoulos, David A Wood, Jose Luis Zamorano, Marie-Therese Cooney
No abstract text is available yet for this article.
October 14, 2016: European Heart Journal
https://read.qxmd.com/read/26294976/clinical-use-of-diuretics-in-heart-failure-cirrhosis-and-nephrotic-syndrome
#17
REVIEW
Ahmed Hassaan Qavi, Rida Kamal, Robert W Schrier
Diuretics play significant role in pharmacology and treatment options in medicine. This paper aims to review and evaluate the clinical use of diuretics in conditions that lead to fluid overload in the body such as cardiac failure, cirrhosis, and nephrotic syndrome. To know the principles of treatment it is essential to understand the underlying pathophysiological mechanisms that cause the need of diuresis in the human body. Various classes of diuretics exist, each having a unique mode of action. A systemic approach for management is recommended based on the current guidelines, starting from thiazides and proceeding to loop diuretics...
2015: International Journal of Nephrology
https://read.qxmd.com/read/26521190/hypertonic-saline-in-conjunction-with-high-dose-furosemide-improves-dose-response-curves-in-worsening-refractory-congestive-heart-failure
#18
RANDOMIZED CONTROLLED TRIAL
Salvatore Paterna, Francesca Di Gaudio, Vincenzo La Rocca, Fabio Balistreri, Massimiliano Greco, Daniele Torres, Umberto Lupo, Giuseppina Rizzo, Pietro di Pasquale, Sergio Indelicato, Francesco Cuttitta, Javed Butler, Gaspare Parrinello
INTRODUCTION: Diuretic responsiveness in patients with chronic heart failure (CHF) is better assessed by urine production per unit diuretic dose than by the absolute urine output or diuretic dose. Diuretic resistance arises over time when the plateau rate of sodium and water excretion is reached prior to optimal fluid elimination and may be overcome when hypertonic saline solution (HSS) is added to high doses of furosemide. METHODS: Forty-two consecutively hospitalized patients with refractory CHF were randomized in a 1:1:1 ratio to furosemide doses (125 mg, 250 mg, 500 mg) so that all patients received intravenous furosemide diluted in 150 ml of normal saline (0...
October 2015: Advances in Therapy
https://read.qxmd.com/read/26385583/management-of-heart-failure-with-preserved-ejection-fraction-a-review
#19
REVIEW
Shane Nanayakkara, David M Kaye
PURPOSE: The purpose of this article was to review the clinical management of patients with heart failure with preserved ejection fraction (HFPEF). METHODS: For this critical review, electronic databases (MEDLINE, EMBASE, PubMed) were searched for relevant basic research studies and randomized clinical trials recently published or presented at major meetings. Details of in-progress or planned studies were obtained from the ClinicalTrials.gov website. The range of publication dates was the year 2000 to 2015...
October 1, 2015: Clinical Therapeutics
https://read.qxmd.com/read/27206819/2016-esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart-failure-the-task-force-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart-failure-of-the-european-society-of-cardiology-esc-developed-with-the-special-contribution-of-the
#20
JOURNAL ARTICLE
Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska, Mariell Jessup, Cecilia Linde, Petros Nihoyannopoulos, John T Parissis, Burkert Pieske, Jillian P Riley, Giuseppe M C Rosano, Luis M Ruilope, Frank Ruschitzka, Frans H Rutten, Peter van der Meer
No abstract text is available yet for this article.
July 14, 2016: European Heart Journal
label_collection
label_collection
7756
1
2
2016-09-10 00:21:33
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.